Every few minutes, the transmitter ... of life for diabetic patients by enhancing comfort, reducing invasive procedures, and enabling better management of blood glucose levels. Recently, the US Food ...

"Partnering with OURA gives us the opportunity to redefine the category again, integrating data from Dexcom glucose ...

Smart ring maker Oura Health Oy is getting a $75 million investment from medical device firm Dexcom Inc., setting the stage for the two companies to share data and cross-sell products.

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

Oura has announced a strategic partnership with continuous glucose monitoring system maker Dexcom. The Finnish wearable maker ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

Dave Ramsey is known today as a straight-talking personal finance expert. But before becoming a household name, Ramsey went ...

Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S. declined year over year despite overall sales coming in slightly ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.